🔎 Trials Near Me

Home › Postural Orthostatic Tachycardia Syndrome › NCT00409435

A Study of Pyridostigmine in Postural Tachycardia Syndrome

RecruitingPhase 2

Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome

Who can join

Ages 15 to 55 · All sexes

Full eligibility criteria
Inclusion Criteria:

Diagnosis of postural tachycardia syndrome using the following criteria:

* Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.
* Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

Both criteria must be fulfilled.

Exclusion Criteria:

* Pregnant or lactating women
* Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study
* Hypothyroidism or hyperthyroidism
* Clinically significant coronary artery disease
* Medications that could interfere with autonomic testing
* Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month

About the study

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

What is being tested

Sponsor: Mayo Clinic · Participants: 50 · Started: 2006-10

Contact the study team

Official record on ClinicalTrials.gov — NCT00409435

Locations in the U.S.

MinnesotaMayo Clinic, Rochester

Conditions

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.